Services

Histology

Pharmacology

Medical Device Testing

In Vitro Screening

Animal Model Development

Custom Assay Development

Vivarium Rental

Toxicology

Species

Non-human Primates

Dogs

Mini-pigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Career

Request a Quote

Logo
☰
  • Services ⌄
    • Histology
    • Pharmacology
    • Medical Device Testing
    • In Vitro Screening
    • Animal Model Development
    • Custom Assay Development
    • Vivarium Rental
    • Toxicology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Mini-pigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Career
    • Request a Quote

ICH Finalizes Revised Quality Risk Management Guideline

  • Post author:PacConAdmin
  • Post published:January 30, 2023
  • Post category:Drug Industry Daily

The International Council for Harmonization (ICH) has issued the final version of its revised guideline on quality risk management ICH Q9(R1), adding information on risk management methodology, such as assessing…

Continue ReadingICH Finalizes Revised Quality Risk Management Guideline

FDA Issues Draft Guidance on Externally Controlled Trials

  • Post author:PacConAdmin
  • Post published:January 30, 2023
  • Post category:Drug Industry Daily

The FDA says trial sponsors and investigators may use patient-level data from other trials and/or real-world data (RWD) sources as an external control arm in a new draft guidance. Source:…

Continue ReadingFDA Issues Draft Guidance on Externally Controlled Trials

LGM Pharma Enters Consent Decree Following Allegations of Adulterated Drugs

  • Post author:PacConAdmin
  • Post published:January 30, 2023
  • Post category:Drug Industry Daily

A federal court in Florida has issued a consent decree against LGM Pharma, a Boca Raton-based active pharmaceutical ingredient (API) importer and distributor, prohibiting the company from distributing APIs that…

Continue ReadingLGM Pharma Enters Consent Decree Following Allegations of Adulterated Drugs

Appeals Court Decides in Favor of Pharma in 340B Battle

  • Post author:PacConAdmin
  • Post published:January 30, 2023
  • Post category:Drug Industry Daily

A federal appeals court has ruled that companies participating in the 340B drug pricing program may restrict discounts to hospitals that use multiple contract pharmacies, handing appellants Sanofi, Novo Nordisk…

Continue ReadingAppeals Court Decides in Favor of Pharma in 340B Battle

Amgen Launches Long-Approved Humira Biosimilar Amjevita

  • Post author:PacConAdmin
  • Post published:January 30, 2023
  • Post category:Drug Industry Daily

Amgen finally launched Amjevita (adalimumab-atto) in the U.S. yesterday, releasing the first rival to AbbVie’s mega-blockbuster anti-inflammatory drug, Humira. Source: Drug Industry Daily

Continue ReadingAmgen Launches Long-Approved Humira Biosimilar Amjevita

Sen. Warren Presses FTC to Scrutinize Two Pending Pharma Mergers

  • Post author:PacConAdmin
  • Post published:January 29, 2023
  • Post category:Drug Industry Daily

Sen. Elizabeth Warren (D-Mass.) has asked the Federal Trade Commission (FTC) to take a hard look at two pending pharmaceutical mergers she believes could impact drug prices. Source: Drug Industry…

Continue ReadingSen. Warren Presses FTC to Scrutinize Two Pending Pharma Mergers

Senators Re-Introduce Bill to Create USPTO-FDA Task Force

  • Post author:PacConAdmin
  • Post published:January 29, 2023
  • Post category:Drug Industry Daily

A bipartisan group of senators has re-introduced proposed legislation to establish a task force between the U.S. Patent and Trademark Office (USPTO) and the FDA to improve coordination in implementing…

Continue ReadingSenators Re-Introduce Bill to Create USPTO-FDA Task Force

FDA Pulls Evusheld EUA, But AstraZeneca Has Another Antibody in The Wings

  • Post author:PacConAdmin
  • Post published:January 29, 2023
  • Post category:Drug Industry Daily

The FDA has pulled the Emergency Use Authorization (EUA) for AstraZeneca’s Evusheld (tixagevimab/cilgavimab) because, the agency says, more than 90 percent of the circulating SARS-CoV-2 variants in the U.S. are…

Continue ReadingFDA Pulls Evusheld EUA, But AstraZeneca Has Another Antibody in The Wings

Dozens of Pediatric Trials Failed to Properly Report Results, Study Finds

  • Post author:PacConAdmin
  • Post published:January 29, 2023
  • Post category:Drug Industry Daily

Nearly four dozen pediatric clinical trials involving more than 3,600 children failed to publish their findings on ClinicalTrials.gov or in scientific literature, according to a new analysis by U.K.-based trial…

Continue ReadingDozens of Pediatric Trials Failed to Properly Report Results, Study Finds

AdComm Recommends Combining Primary and Booster COVID Strains in One Annual Shot

  • Post author:PacConAdmin
  • Post published:January 26, 2023
  • Post category:Drug Industry Daily

An FDA advisory committee yesterday recommended that the next generation of COVID-19 vaccines should combine the current primary vaccine against the original Wuhan strain and the bivalent booster against Omicron…

Continue ReadingAdComm Recommends Combining Primary and Booster COVID Strains in One Annual Shot
  • Go to the previous page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • …
  • 385
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:

6042 Cornerstone Court W

Suite E

San Diego, CA 92121

Social:
© 2025 BioLegacy Research. All rights reserved.